Should I Buy Census Healthcare (SRTS)? Finance YouTuber Analysis

Hogue recommends Census Healthcare (SRTS), a medical device maker for non-invasive radiation therapy for skin cancers. He notes its unique FDA-cleared system for children and a high success rate. Despite volatile revenue, it rebounded 69% last year and is strongly profitable with a 29% operating margin, with analysts forecasting 24% revenue growth for the next year.

“The revenue here has been up and down but did Rebound 69% in the last year and this one is strongly profitable at a 29% operating margin”

The YouTuber recommends Census Healthcare (SRTS) due to its strong sales growth and profitability. The company, a medical device maker for skin cancer treatment, is profitable and expected to grow revenue by 30% to over $41 million, with an estimated $0.47 EPS. Its EBITDA margin of 18% on $31 million revenue is also highlighted.

“The company is already profitable and expected to grow Revenue at an average 30% between this year and next to over $41 million and to report 47 cents in per share income census booked $5.7 million in eida over the last year a profitability margin of 18% on its $31 million in revenue and and that profitability should improve as the recurring Revenue grows to be a bigger part of this total.”

The YouTuber recommends Cenntro Healthcare, a medical device maker for non-invasive radiation therapy. He highlights its profitability, expected 30% revenue growth, and 18% EBITDA margin, which contribute to a strong 'Rule of 40' score. The company's unique FDA-cleared system for treating skin cancers in children is also a key factor.

“Cenntro Healthcare ticker srts a medical device maker for non-invasive radiation therapy for certain types of skin cancers in fact census is the only company with an FDA cleared system to treat kids and has a 97% success rate on the procedure.”